CA3233319A1 - Resmetirom for reducing liver volume - Google Patents
Resmetirom for reducing liver volume Download PDFInfo
- Publication number
- CA3233319A1 CA3233319A1 CA3233319A CA3233319A CA3233319A1 CA 3233319 A1 CA3233319 A1 CA 3233319A1 CA 3233319 A CA3233319 A CA 3233319A CA 3233319 A CA3233319 A CA 3233319A CA 3233319 A1 CA3233319 A1 CA 3233319A1
- Authority
- CA
- Canada
- Prior art keywords
- resmetirom
- subject
- prodrug
- less
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248634P | 2021-09-27 | 2021-09-27 | |
| US63/248,634 | 2021-09-27 | ||
| PCT/US2022/044826 WO2023049491A1 (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233319A1 true CA3233319A1 (en) | 2023-03-30 |
Family
ID=83900064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233319A Pending CA3233319A1 (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240408102A1 (https=) |
| EP (2) | EP4408428A1 (https=) |
| JP (1) | JP2024536126A (https=) |
| KR (1) | KR20240073926A (https=) |
| CN (1) | CN118251221A (https=) |
| AR (1) | AR127165A1 (https=) |
| AU (1) | AU2022348966A1 (https=) |
| CA (1) | CA3233319A1 (https=) |
| CL (1) | CL2024000886A1 (https=) |
| IL (1) | IL311670A (https=) |
| MX (1) | MX2024003967A (https=) |
| TW (1) | TW202337470A (https=) |
| WO (1) | WO2023049491A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121443313A (zh) * | 2023-06-08 | 2026-01-30 | 成都微芯药业有限公司 | PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途 |
| WO2024263714A1 (en) * | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| KR20260000642A (ko) * | 2024-06-25 | 2026-01-05 | 연세대학교 산학협력단 | Usp10 억제제를 유효성분으로 포함하는, 간섬유증 또는 간섬유증 관련 질환의 예방 또는 치료용 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
-
2022
- 2022-09-27 CN CN202280075697.1A patent/CN118251221A/zh active Pending
- 2022-09-27 TW TW111136510A patent/TW202337470A/zh unknown
- 2022-09-27 JP JP2024519112A patent/JP2024536126A/ja active Pending
- 2022-09-27 US US18/695,572 patent/US20240408102A1/en active Pending
- 2022-09-27 EP EP22793025.2A patent/EP4408428A1/en not_active Withdrawn
- 2022-09-27 EP EP24212126.7A patent/EP4578499A3/en active Pending
- 2022-09-27 AR ARP220102600A patent/AR127165A1/es unknown
- 2022-09-27 AU AU2022348966A patent/AU2022348966A1/en active Pending
- 2022-09-27 KR KR1020247013928A patent/KR20240073926A/ko active Pending
- 2022-09-27 IL IL311670A patent/IL311670A/en unknown
- 2022-09-27 WO PCT/US2022/044826 patent/WO2023049491A1/en not_active Ceased
- 2022-09-27 CA CA3233319A patent/CA3233319A1/en active Pending
- 2022-09-27 MX MX2024003967A patent/MX2024003967A/es unknown
-
2024
- 2024-03-26 CL CL2024000886A patent/CL2024000886A1/es unknown
-
2025
- 2025-11-12 US US19/386,839 patent/US20260069598A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202337470A (zh) | 2023-10-01 |
| EP4408428A1 (en) | 2024-08-07 |
| JP2024536126A (ja) | 2024-10-04 |
| CN118251221A (zh) | 2024-06-25 |
| US20260069598A1 (en) | 2026-03-12 |
| IL311670A (en) | 2024-05-01 |
| WO2023049491A1 (en) | 2023-03-30 |
| AR127165A1 (es) | 2023-12-27 |
| AU2022348966A1 (en) | 2024-04-11 |
| KR20240073926A (ko) | 2024-05-27 |
| EP4578499A3 (en) | 2025-09-17 |
| CL2024000886A1 (es) | 2024-08-30 |
| EP4578499A2 (en) | 2025-07-02 |
| MX2024003967A (es) | 2024-06-03 |
| US20240408102A1 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260069598A1 (en) | Resmetirom for reducing liver volume | |
| US11400072B2 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
| JP6941109B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| JP6986022B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| JP6441267B2 (ja) | 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ | |
| KR102412997B1 (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| CN105764498A (zh) | 纯合家族型高胆固醇血症的治疗 | |
| CN105228622B (zh) | 用于治疗多发性硬化的PPARγ激动剂 | |
| TW200918049A (en) | Compounds useful as medicaments | |
| CN115227825A (zh) | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 | |
| US20200276178A1 (en) | Combinations comprising fxr agonists | |
| US20260097039A1 (en) | Methods for treating a fatty liver disease | |
| WO2024041596A1 (zh) | 苯妥英钠作为线粒体自噬诱导剂的用途 | |
| HK40128789A (en) | Resmetirom for reducing liver volume | |
| KR101893551B1 (ko) | 치료 방법 | |
| US20240423992A1 (en) | Biomarkers for treating liver disorders with thr-b agonists and related uses | |
| US9226926B2 (en) | Therapeutic agent for lower urinary tract disease | |
| US20250161326A1 (en) | Combination therapy | |
| CN114401745A (zh) | 包含fxr激动剂的治疗 | |
| WO2025250918A1 (en) | Novel compositions | |
| JP2023522062A (ja) | 代謝異常を治療するためのベンズイミダゾール化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250919 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |